This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.


Our Awards

In 2019, ITM won the German Medical Award in the category “Medical Innovation Product”, honored for its Targeted Radionuclide Therapy approach. The German Medical Award recognizes medical professionals, clinics and companies from the healthcare industry for their dedication and commitment to advanced patient care. ITM received the award in recognition of its contribution to the improvement of outcomes and quality of life of cancer patients and its continued research and development of targeted diagnostic and therapeutic radiopharmaceuticals.

The year before, ITM received the Pharma Trend Award 2018 "Most Innovative Product" in the Startup category. An interdisciplinary jury of six pharma representatives evaluated German pharmaceutical companies in terms of innovation and sustainability. The criteria of patient benefit, innovation, efficient patient care and integration in the German statutory insurance scheme were particularly decisive for the jury in the assessment of the products and projects submitted for the category in which ITM took part.

In the same year, ITM was also honored with the Red Herring Top 100 Europe Award that recognizes Europe’s leading private companies, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Europe selects the award winners from approximately 1,200 privately financed companies each year, based on both quantitative and qualitative criteria, such as financial performance, technological innovation, management quality, overall business strategy and market penetration. In 2018, ITM was awarded for its promising Targeted Radionuclide Therapy in Precision Oncology.

In 2017, ITM was awarded the Deloitte Technology Fast 50 Award for leader in life sciences industry. The results were based on the percentage of sales growth during the past four financial years (2013-2016), in which ITM achieved a sales growth of 174%. ITM’s success can be majorly contributed to the self-developed technology of Targeted Radionuclide Diagnostics and Therapies.